The acquisition transforms Biogen's near-term growth profile with two approved products and a pipeline catalyst in nephrology. Monitor Q2 2026 earnings for updated financial guidance incorporating Apellis, and track SYFOVRE sales trajectory for CVR payout potential. The deal removes Apellis overhang and provides a clear revenue growth driver beyond Biogen's legacy neurology franchise.
BIIB drugs
BIIB drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 14 $191.26entry
- T+1 · 6mo ago +0.55%α +1.78% · $192.32
- T+5 · 6mo ago −1.23%α −0.52% · $188.90
- T+20 · 5mo ago +4.60%α +5.46% · $200.05
- T+60 · 3mo ago +8.15%α +4.83% · $206.85
Price Chart
How similar events traded
Executive Summary
Biogen completed its acquisition of Apellis Pharmaceuticals for $41 per share in cash plus up to $4 per share in contingent value rights, adding two commercial products (EMPAVELI and SYFOVRE) that generated $689 million in combined 2025 net product revenue. The deal is expected to be accretive to Biogen's non-GAAP EPS in 2027 and materially increase its non-GAAP EPS CAGR through the end of the decade, while expanding Biogen into nephrology ahead of a key Phase 3 readout for felzartamab in 2027.
Key Financial Metrics
Key Facts
- Biogen acquired Apellis for $41 per share in cash plus up to $4 per share in CVRs tied to SYFOVRE sales thresholds.
- Approximately 105.7 million shares (82.4% of outstanding) were tendered; remaining shares converted at the same price.
- EMPAVELI and SYFOVRE generated $689 million in combined net product revenue in 2025.
- The acquisition is expected to be accretive to Biogen's non-GAAP diluted EPS in 2027 and materially increase non-GAAP EPS CAGR through the end of the decade.
- Apellis brings established nephrology commercial infrastructure to support felzartamab launch, with first Phase 3 readout in antibody-mediated rejection expected in H1 2027.
Financial Impact
Total consideration of approximately $4.3 billion in cash plus up to $420 million in CVRs based on 105.7M shares tendered at $41/share plus $4/share CVR; combined acquired products had $689M in 2025 revenue.
Risk Factors
- Integration risk: realizing expected synergies and maintaining Apellis product sales momentum.
- SYFOVRE faces competition from Iveric Bio's avacincaptad pegol (Izervay) in geographic atrophy.
- CVR payments depend on achieving SYFOVRE net sales thresholds, which may not be met.
- Felzartamab Phase 3 readout in 2027 is binary and may not succeed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294955 |
Track record
34 reports on BIIB
9 of 11 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jul 13, 2026 report. 15 of 16 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Neutral 3/10 Entry $253.40 Now $251.65 −0.69% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $253.25 Now $251.65 −0.63% settles Feb 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $254.87 Now $251.65 −1.26% settles Feb 5
- Oct 28, 202619d ago Institutional Cluster Neutral 2/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
- Oct 19, 202628d ago Press Release Neutral 4/10 Entry $233.48 Now $251.65 +7.78% settles Jan 14
- Oct 12, 20265w ago ANALYST-UPGRADE Bullish 6/10 Entry $229.41 Now $251.65 +9.69% settles Jan 7
- Oct 2, 20266w ago Press Release Bullish 6/10 Entry $219.88 Now $251.65 +14.45% settles Dec 29
- Sep 17, 20268w ago Press Release Bullish 5/10 Entry $215.50 Now $251.65 +16.77% settles Dec 14
- Sep 3, 202610w ago Press Release Neutral 4/10 Entry $220.83 Now $251.65 +13.96% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers